Source comparison
CJC-1295 No DAC & Ipamorelin: Administration Comparison
Typical Research Dose 100–200 mcg per injection 100–200 mcg each, co-administered Co-administration produces synergistic GH release 3–5× greater than either peptide alone Half-Life ~30 minutes ~2 hours N/A CJC-1295 No DAC's short half-life requires multiple da
This comparison does not assign a generated winner or score.
- Typical Research Dose
- 100–200 mcg per injection
- 100–200 mcg each, co-administered
- Co-administration produces synergistic GH release 3–5× greater than either peptide alone
- Half-Life
- ~30 minutes
- ~2 hours
- N/A
- CJC-1295 No DAC's short half-life requires multiple daily doses or pairing with longer-acting peptides
- Dosing Frequency
- 1–3 times daily
- 1–3 times daily, same timing
- Most research protocols use 2× daily (morning fasted + pre-sleep) for metabolic studies
- Optimal Timing
- Pre-sleep, post-exercise, fasted morning
- Align with endogenous GH pulse windows
- Pre-sleep administration captures the largest endogenous GH pulse, maximizing synergistic effect
- Receptor Selectivity
- GHRH receptor agonist
- Ghrelin receptor (GHSR-1a) agonist
- Dual-pathway stimulation
- Complementary receptor targeting explains why combination protocols dominate GH research
- Side Effect Profile
- Minimal; transient injection site redness
- Minimal; no cortisol/prolactin elevation
- Low side effect incidence when dosed correctly
- Ipamorelin's selectivity avoids the cortisol spike seen with GHRP-6, making it preferable for long-term studies